Question | Discussion | References | CME Credit

Case 2: References

  1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. May 4, 2006. Available at:
    [The following link will open in a new window. AIDSinfo - Accessed September 6, 2006]
  2. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;191:825-9.
    [The following link will open in a new window. PubMed Abstract]
  3. U.S. Food and Drug Administration. FDA public health advisory for nevirapine (Viramune). Available at:
    [The following link will open in a new window. U.S. Food and Drug Administration - Accessed September 14, 2006]
  4. Piliero PJ, Purdy B. Nevirapine-induced hepatitis: a case series and review of the literature. AIDS Read. 2001;11:379-82.
    [The following link will open in a new window. PubMed Abstract]
  5. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 2001;15:1261-8.
    [The following link will open in a new window. PubMed Abstract]
  6. Prakash M, Poreddy V, Tiyyagura L, Bonacini M. Jaundice and hepatocellular damage associated with nevirapine therapy. Am J Gastroenterol. 2001;96:1571-4.
    [The following link will open in a new window. PubMed Abstract]
  7. De Maat MM, Ter Heine R, Van Gorp EC, Mulder JW, Mairuhu AT, Beijnen JH. Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. AIDS. 2003;17:2209-14.
    [The following link will open in a new window. PubMed Abstract]
  8. Martin-Carbonero L, Nunez M, Gonzalez-Lahoz J, Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials. 2003;4:115-20.
    [The following link will open in a new window. PubMed Abstract]
  9. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr. 2003;34 Suppl 1:S21-33.
    [The following link will open in a new window. PubMed Abstract]
  10. De Maat MM, Mathot RA, Veldkamp AI, et al. Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals. Pharmacol Res. 2002;46:295-300.
    [The following link will open in a new window. PubMed Abstract]
  11. Lyons F, Hopkins S, Kelleher B, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med. 2006;7:255-60.
    [The following link will open in a new window. PubMed Abstract]
  12. Gonzalez de Requena D, Nunez M, Jimenez-Nacher I, Soriano V. Liver toxicity caused by nevirapine. AIDS. 2002;16:290-1.
    [The following link will open in a new window. PubMed Abstract]
  13. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep. 2001;49(51-52):1153-6. Available at:
    [The following link will open in a new window. Centers for Disease Control and Prevention - Accessed April 1, 2005]
  14. Knobel H, Miro JM, Domingo P, et al. Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study. J Acquir Immune Defic Syndr. 2001;28:14-8.
    [The following link will open in a new window. PubMed Abstract]

[Back to Case 2 Question | Back to Discussion]

CME Credit | Back to Top